GlassScriptPhysician profile
Julilyn Brown
NPI 1003508250
$5,281.92
in general payments reported to CMS, 2019-2025
19 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,119 · 2024: $1,833 · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.77 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,015.91 | 2024-2025 | Cobenfy |
| Abbvie INC. | $735.47 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $678.94 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $627.86 | 2023-2025 | Auvelity |
| Lundbeck LLC | $390.98 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $379.19 | 2023-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $238.99 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $228.30 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $213.96 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $167.62 | 2023-2025 | Azstarys |
| Tris Pharma INC | $117.36 | 2023-2025 | Dyanavel Xr |
| Indivior INC. | $111.07 | 2023-2024 | Perseris, Sublocade |
| Alkermes, INC. | $93.94 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $76.29 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neos Therapeutics, LP | $58.74 | 2024 | Adzenys Xr-Odt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $57.94 | 2024-2025 | Fanapt |
| Noven Therapeutics, LLC | $41.86 | 2023-2024 | Xelstrym, Secuado |
| Almatica Pharma LLC | $33.05 | 2023-2025 | Gralise, Loreev Xr |
| Supernus Pharmaceuticals, INC. | $14.45 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julilyn Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.